Myriad Oncology Molecular Tumor Board Series

Join Myriad Oncology and Clarified Health as we partner together on a cutting-edge Molecular Tumor Board Series

We are excited to announce our continued partnership with Clarified Precision Medicine on the 2025 Molecular Tumor Board Series. Join our virtual tumor board to engage with leading cancer experts as they discuss the latest patient cases, utilizing combined germline and comprehensive tumor genomic profiling, to inform treatment decisions.

These Myriad Oncology Molecular Tumor Boards aim to bring together clinicians and their support staff to engage with leading cancer experts discussing 4 unique patient cases to interpret molecular findings to identify therapeutic decisions and outcomes.

Key highlights include:

State-of-the-art and evidence-based assessment of Myriad Oncology’s tests and results
Summarized, and de-identified, patient cases focusing on germline and tumor genomic landscapes
Discussion of hereditary implications of genomic findings
Prioritization of targeted therapy options based on genomic findings

Event Details:

Explore targeted therapies and management options for gastrointestinal cancer patients based on germline and genomic findings.

Thursday, May 15 from 5pm – 6pm ET

Join us for our first session of our quarterly Molecular Tumor Board, held in partnership with Clarified Health. This first session will focus on gastrointestinal cancer, providing comprehensive insights from tumor genomic profiling and germline results. We will discuss all critical biomarker results necessary for an informed discussion guiding treatment decisions.